KMDA Stock Analysis: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$8.32
-0.05 (-0.60%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 04, 2026
29d
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KMDA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: KMDA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.14
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.40
11.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $8.32, which is considered slightly high relative to its 30-day fair value range of $7.28 to $8.36. The stock's valuation (Forward PE: 17.3) is in line with its historical norms (16.2). At these levels, the market is pricing in 2.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KMDA is in a uptrend. Immediate support is located at $7.66, while resistance sits at $8.88.
Market Sentiment: KMDA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.00 (+56.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KMDA is in a uptrend. Immediate support is located at $7.66, while resistance sits at $8.88.
Market Sentiment: KMDA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.00 (+56.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$7.28 -
$8.36
Company Quality Score
61/100
(BUY)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.2% below Wall St target ($13.00)
- NEUTRAL: Market pricing in 2.3% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$7.28 -
$8.36
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.93
(11.2%)
Support & Resistance Levels
Support Level
$7.66
Resistance Level
$8.88
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
17.33
Wall Street Target
$13.00
(+56.2%)
Revenue Growth (YoY)
12.6%
Earnings Growth (YoY)
28.6%
Profit Margin
11.7%
Valuation Premium vs History
+2.3% premium
PE vs Historical
17.3 vs 16.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.3%
(market-implied from PE analysis)
1-Year Target
$8.51
(+2%)
2-Year Target
$8.71
(+5%)
3-Year Target
$8.91
(+7%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$8.32
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 30.6%)
$23.85
(+187%)
Base:
(SPY PE: 17.3, Growth: 30.6%)
$18.54
(+123%)
Bear:
(PE: 14.7, Growth: 30.6%)
$15.76
(+89%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 24.69 | Current EPS (TTM): $0.35
Bull Case
$13.03
(+57%)
Analyst growth 37.1%, PE expands to 27.2
Base Case
$11.85
(+42%)
Market implied 37.1%, PE stable at 24.7
Bear Case
$5.88
(-29%)
Severe decline -20.0%, PE contracts to 21.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 01, 2026 6:21 PM ET
Data refreshes hourly during market hours. Next update: 7:21 PM
Data refreshes hourly during market hours. Next update: 7:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
